The potential for medication mix-ups worries patients most, followed by fear of negative drug interactions and treatment costs.
A new study by the American Society of Health-System Pharmacists reveals that the potential for medication mix-ups worries patients most, followed by fear of negative drug interactions and treatment costs.
The study, which examined 10 common patient concerns in hospitals and other component health systems, was conducted among more than 1,000 adults age 18 and older.
Many Americans have a relatively high level of anxiety surrounding hospital or health system visits, the study revealed. When asked, the majority of respondents said they were "very concerned" about a number of issues including being given the wrong medication (61%), being given two or more medications that react in a negative way (58%), the cost of treatment (58%), complications from medical procedures (56%), getting an infection (50%) and suffering from pain (49%).
"With more and more sophisticated drugs entering the market today, patients are increasingly worried about the accuracy, safety and appropriate monitoring of their medications to ensure the best outcomes," said Bruce Scott, president of ASHP. "This study shows that patients need to feel more comfortable about their pharmaceutical treatments."
Seventy-six percent of respondents also added that speaking with a pharmacist while in the hospital or health system would help allay their medication concerns. These results are particularly enlightening due to the fact that a 1998 ASHP study revealed that patients often don't realize that pharmacists are part of a hospital's patient care team. When asked to name health care providers who work in hospitals, only 1% of those surveyed in the 1998 study named pharmacists.
"Pharmacists are a great resource for medication information and are available to speak directly with patients and their families about the medications they receive while in the hospital or health system," said Scott. "These new data should also be helpful to hospitals and health systems across the country so that health care professionals can help lower the level of patient anxiety regarding medication use." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.